Total Payments
$57,960
2024 Payments
$14,245
Companies
4
Transactions
32
Payment Breakdown by Category
Consulting$53,407 (92.1%)
Travel$2,312 (4.0%)
Research$1,743 (3.0%)
Food & Beverage$497.75 (0.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $53,407 | 12 | 92.1% |
| Travel and Lodging | $2,312 | 6 | 4.0% |
| Unspecified | $1,743 | 4 | 3.0% |
| Food and Beverage | $497.75 | 10 | 0.9% |
Payments by Type
General
$56,217
28 transactions
Research
$1,743
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $22,495 | 5 | $0 (2024) |
| Janssen Research & Development, LLC | $18,200 | 4 | $0 (2018) |
| Alkermes, Inc. | $9,138 | 9 | $0 (2018) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $8,127 | 14 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,245 | 3 | Neurocrine Biosciences, Inc. ($14,245) |
| 2023 | $8,250 | 2 | Neurocrine Biosciences, Inc. ($8,250) |
| 2020 | $1,743 | 4 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($1,743) |
| 2018 | $13,863 | 10 | Alkermes, Inc. ($9,138) |
| 2017 | $19,860 | 13 | Janssen Research & Development, LLC ($13,475) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/27/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,465.00 | General |
| 08/02/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,575.00 | General |
| 03/29/2024 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,205.00 | General |
| 08/25/2023 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,712.50 | General |
| 02/23/2023 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,537.50 | General |
| 03/01/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $725.74 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 03/01/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $142.69 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 02/28/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $731.66 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 02/28/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $142.69 | Research |
| Study: BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD • Category: PSYCHIATRY | ||||||
| 12/27/2018 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $4,725.00 | General |
| 12/17/2018 | Alkermes, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,500.00 | General |
| 12/17/2018 | Alkermes, Inc. | — | Travel and Lodging | In-kind items and services | $110.90 | General |
| 12/17/2018 | Alkermes, Inc. | — | Food and Beverage | In-kind items and services | $51.65 | General |
| 10/30/2018 | Alkermes, Inc. | — | Food and Beverage | In-kind items and services | $23.54 | General |
| 10/29/2018 | Alkermes, Inc. | — | Travel and Lodging | In-kind items and services | $732.40 | General |
| 10/29/2018 | Alkermes, Inc. | — | Travel and Lodging | In-kind items and services | $569.96 | General |
| 10/29/2018 | Alkermes, Inc. | — | Food and Beverage | In-kind items and services | $64.55 | General |
| 10/29/2018 | Alkermes, Inc. | — | Food and Beverage | In-kind items and services | $61.04 | General |
| 10/29/2018 | Alkermes, Inc. | — | Food and Beverage | In-kind items and services | $23.54 | General |
| 11/14/2017 | Otsuka Pharmaceutical Development & Commercialization, Inc. | BREXPIPRAZOLE (Drug) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: PSYCHIATRY | ||||||
| 08/02/2017 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $4,375.00 | General |
| 07/28/2017 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MAINTENA (Drug) | Consulting Fee | Cash or cash equivalent | $4,912.15 | General |
| Category: PSYCHIATRY | ||||||
| 07/28/2017 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MAINTENA (Drug) | Travel and Lodging | Cash or cash equivalent | $101.96 | General |
| Category: PSYCHIATRY | ||||||
| 07/28/2017 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | Cash or cash equivalent | $38.75 | General |
| Category: PSYCHIATRY | ||||||
| 07/28/2017 | Otsuka Pharmaceutical Development & Commercialization, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | Cash or cash equivalent | $9.73 | General |
| Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALINE IN TREATMENT OF ADULTS WITH PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,743 | 4 |
About Dr. Michael Ostacher, MD
Dr. Michael Ostacher, MD is a Forensic Psychiatry healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093789083.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Ostacher, MD has received a total of $57,960 in payments from pharmaceutical and medical device companies, with $14,245 received in 2024. These payments were reported across 32 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($53,407).
Ad
Practice Information
- Specialty Forensic Psychiatry
- Other Specialties Addiction Medicine, Psychiatry
- Location Boston, MA
- Active Since 02/15/2006
- Last Updated 05/03/2013
- Taxonomy Code 2084F0202X
- Entity Type Individual
- NPI Number 1093789083
Products in Payments
- ABILIFY MAINTENA (Drug) $5,063
- REXULTI (Drug) $1,743
- ABILIFY TABLET (Drug) $1,022
- BREXPIPRAZOLE (Drug) $300.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Forensic Psychiatry Doctors in Boston
Dr. Brian Keefe, Md, MD
Forensic Psychiatry — Payments: $6,406
Forensic Psychiatry $6,406
Stephanie Taormina, Md, MD
Forensic Psychiatry — Payments: $372.88
Forensic Psychiatry $372.88
Dr. Susan Swick, Md, MD
Forensic Psychiatry
Forensic Psychiatry
Dr. Ronald Schouten, Md, MD
Forensic Psychiatry
Forensic Psychiatry
Dr. Donald Condie, Md, MD
Forensic Psychiatry
Forensic Psychiatry
Dr. Pamela Beasley, Md, MD
Forensic Psychiatry
Forensic Psychiatry